Bristol-Myers Squibb Co DRC (BMY)

Get an in-depth profile of Bristol-Myers Squibb Co DRC, including a general overview of the company's business and key management, as well as employee data and location and contact information.

10,764.50 -222.00 (-2.02%)

24/05 Closed ARS Disclaimer

Bristol-Myers Squibb Co DRC Company Profile

Industry: Pharmaceuticals
Sector: Healthcare
Employees: 32200
Equity Type: DRC

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Contact Information

Address: New York,10016 United States
Phone: 212 546 4000
Fax: -
Web: https://www.bms.com

Top Executives

Name	Age	Since	Title
Giovanni Caforio	57	2011	Chairman of the Board & CEO
Paula A. Price	62	2020	Independent Director
Gerald L. Storch	66	2012	Independent Director
Derica W. Rice	58	2020	Independent Director
Christopher S. Boerner	52	2018	Executive VP, COO & Director
Theodore Rapp Samuels	68	2017	Lead Independent Director
Peter J. Arduini	58	2016	Independent Director
Karen H. Vousden	65	2018	Independent Director
Deepak L. Bhatt	55	2022	Independent Director
Phyllis R. Yale	66	2019	Independent Director
Manuel Hidalgo Medina	55	2021	Independent Director
Julia A. Haller	68	2019	Independent Director

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.